Urgent.News

What's breaking now, across thousands of outlets.

Business

Option-to-acquire deals remain rare in biotech's buzzy M&A season

Two recent deals are focusing attention on a relatively rare structure for biotech buyouts: the option-to-acquire. Drug developers are on pace to have one of the best dealmaking years in industry history, with more than ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Business

More from Monday 24 August →